Last reviewed · How we verify

Cleanser

Dr.dr.Irma Bernadette, SpKK (K) · FDA-approved active Small molecule Quality 7/100

Cleanser, marketed by Dr.dr.Irma Bernadette, SpKK (K), is an acne treatment currently available in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive positioning.

At a glance

Generic nameCleanser
SponsorDr.dr.Irma Bernadette, SpKK (K)
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: